65,437 trials
Breast Cancer · Drug/Agent Toxicity by Tissue/Organ · Unspecified Adult Solid Tumor, Protocol Specific
Primary: To Determine Whether the Prophylactic Use of a Topical Urea/Lactic Acid Cream Can Decrease the Incidence/Severity of Capecitabine-caused Palmar-plantar…
Dentin Sensitivity
Primary: Change From Baseline in Schiff Sensitivity Score on Day 3 — -0.40; 0.00 Score on a scale — p=<0.0001
Pelvic Pain · Healthy
Primary: Pain Assessment — -2.375; -1.625 units on a scale
Lack of Satiety · Hyperphagia
Primary: Test Meal Energy Intake — 1007.3; 1019.6; 1143.4 kcal — p=<0.01
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: 6 Months Progression-free Survival — 3 percent
Recurrent Thyroid Gland Carcinoma · Stage III Thyroid Gland Follicular Carcinoma · Stage III Thyroid Gland Papillary Carcinoma
Primary: Progression-free Survival to Determine the 6-month Progression-free-survival (PFS) Rate — 5.4 months
Psychosis
Primary: Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) — 87.30; 87.30; 88.46; 89.23 units on a scale — p=< .05
Occasional Sleeplessness
Primary: Mean Latency to Persistent Sleep — 19.1; 27.1 minutes — p=0.0312
Methicillin-Resistant Staphylococcus Aureus
Primary: MRSA Transmission — 0.20; 0.02; 0.11; 0.01 Proportion of swabs positive for MRSA
Menopause
Primary: Menopause Quality Of Life Questionnaire (MENQOL) Physical Domain Subscale — 1.9 units on a scale
Standard Treatment Versus Engagement Focused Treatment
Primary: Subjective Quality of Life — 3.9; 3.8; 4.3; 4.0 units on a scale
Coronary Artery Disease
Primary: Number of Participants With Combination of All Cause Death, Non-fatal Myocardial Infarction (MI), and Hospitalization for Unstable Angina — 34; 28 Participants
Amyotrophic Lateral Sclerosis
Primary: Duration of BCI Usage by Persons With ALS. — 5 months
Bronchiolitis · Wheezing
Primary: Score Respiratory Distress — 8; 8; 6; 8 units on a scale
Obesity
Primary: This Outcome Measure is the Tedizolid Area Under the Concentration Time-curve From Time 0 to 72 Hours in Morbidly Obese Subjects and Matched Non-obese Subjects. — 26.0…